Alto Neuroscience, Inc. Total Assets
Alto Neuroscience, Inc. total assets. Based on the latest financial reports, Alto Neuroscience, Inc. (ANRO) holds total assets worth $184.69 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Alto Neuroscience, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Alto Neuroscience, Inc. (2021–2025)
Total assets of Alto Neuroscience, Inc. from 2021 to 2025. This chart illustrates how Alto Neuroscience, Inc.'s total assets have evolved over time, based on quarterly financial data. See Alto Neuroscience, Inc. share price for real-time trading data and today's change.
Alto Neuroscience, Inc. - Asset Composition Analysis
Alto Neuroscience, Inc. Total Assets Breakdown (September 2025)
Alto Neuroscience, Inc. total assets breakdown as of September 2025. Alto Neuroscience, Inc.'s total assets of $184.69 Million consist of 96.2% current assets and 3.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Alto Neuroscience, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ANRO current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alto Neuroscience, Inc.'s current assets represent 96.2% of total assets in 2025, an increase from 96.2% in 2021.
- Cash Position: Cash and equivalents constituted 95.6% of total assets in 2025, up from 89.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Alto Neuroscience, Inc. Competitors by Total Assets
Key competitors of Alto Neuroscience, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Sinocelltech Group Ltd
SHG:688520
|
China | CN¥3.76 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.47 Billion |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
|
USA | $667.85 Million |
|
GH Research PLC
NASDAQ:GHRS
|
USA | $372.35 Million |
Alto Neuroscience, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.69 | 16.92 | 8.85 |
| Quick Ratio | 15.69 | 16.92 | 8.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $166.39 Million | $159.33 Million | $43.66 Million |
Alto Neuroscience, Inc. - Advanced Valuation Insights
This section examines the relationship between Alto Neuroscience, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.63 |
| Latest Market Cap to Assets Ratio | 4.15 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | $184.69 Million |
| Market Capitalization | $766.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Alto Neuroscience, Inc.'s assets at a significant premium (4.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Alto Neuroscience, Inc.'s assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Alto Neuroscience, Inc. (2021–2025)
The table below shows the annual total assets of Alto Neuroscience, Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $184.69 Million | +4.03% |
| 2024-09-30 | $177.54 Million | +104.95% |
| 2023-09-30 | $86.63 Million | +70.35% |
| 2022-09-30 | $50.85 Million | +76.61% |
| 2021-09-30 | $28.79 Million | -- |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more